MondegarAI
RA CAPITAL MANAGEMENT, L.P.

Q4 2024 · 13F-HR

RA CAPITAL MANAGEMENT, L.P.holdings as filed

Filed 2025-02-14 · accession 0001104659-25-014181

$7.51B
Reported value
89
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
04351P101ASNDUSDASCENDIS PHARMA A/S - ADR$1.39B18.5%10,112,744CommonSOLE
92243G108PCVXVAXCYTE INC$711.3M9.47%8,689,190CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$555.0M7.39%10,365,652CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$340.6M4.53%6,084,412CommonSOLE
52490G102LEGNLEGEND BIOTECH CORP-ADR$244.3M3.25%7,506,934CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$237.9M3.17%8,909,091CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA CO NV$227.3M3.03%8,845,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$225.2M3.00%18,202,009CommonSOLE
03940C100ACLXGBXARCELLX INC$213.8M2.84%2,787,327CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$183.2M2.44%6,300,408CommonSOLE
81734D104SEPNSEPTERNA INC$160.2M2.13%6,995,858CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$150.3M2.00%6,381,144CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$147.9M1.97%10,637,290CommonSOLE
78349D107RXSTRXSIGHT INC$128.7M1.71%3,743,018CommonSOLE
055477103BCAXBICARA THERAPEUTICS INC$121.2M1.61%6,955,993CommonSOLE
52635N103LENZLENZ THERAPEUTICS INC$120.6M1.61%4,178,823CommonSOLE
82835W108SPRYARS PHARMACEUTICALS INC$114.6M1.52%10,860,977CommonSOLE
282559103ETNBGBP89BIO INC$110.9M1.48%14,175,398CommonSOLE
78464A870XBISPDR S&P BIOTECH ETF$110.6M1.47%1,228,240CommonSOLE
374163103GERNGERON CORP$106.2M1.41%30,009,536CommonSOLE
04317A107ARTVARTIVA BIOTHERAPEUTICS INC$99.3M1.32%9,853,302CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$84.6M1.13%1,000,000CommonSOLE
925050106VRNAVERONA PHARMA PLC - ADR$82.1M1.09%1,766,830CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$72.9M0.97%5,755,577CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$71.1M0.95%1,569,491CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$59.7M0.79%4,850,984CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$58.6M0.78%761,955CommonSOLE
28658R106CLYMCLIMB BIO INC$56.6M0.75%31,419,267CommonSOLE
75629V104RXRXRECURSION PHARMACEUTICALS-A$52.2M0.69%7,725,096CommonSOLE
89157D105TRMLTOURMALINE BIO INC$51.5M0.69%2,538,925CommonSOLE
004890109ACRVACRIVON THERAPEUTICS INC$50.2M0.67%8,340,508CommonSOLE
359616109FULCFULCRUM THERAPEUTICS INC$48.1M0.64%10,229,099CommonSOLE
88025U109TXG10X GENOMICS INC-CLASS A$47.1M0.63%3,279,401CommonSOLE
G3855L106GHRSGH RESEARCH PLC$46.8M0.62%6,686,689CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$45.6M0.61%5,105,213CommonSOLE
929033108VOR BIOPHARMA INC$44.0M0.59%39,646,039CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$41.2M0.55%1,517,418CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$40.7M0.54%1,866,400CommonSOLE
713317105PEPGPEPGEN INC$40.5M0.54%10,689,545CommonSOLE
30050B101EVHEVOLENT HEALTH INC - A$40.2M0.54%3,577,197CommonSOLE
50127T109KURAKURA ONCOLOGY INC$38.8M0.52%4,451,041CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$34.6M0.46%1,347,252CommonSOLE
98887Q104ZLABZAI LAB LTD-ADR$33.9M0.45%1,295,040CommonSOLE
16934W106CMRXEURCHIMERIX INC$30.6M0.41%8,800,000CommonSOLE
171757206CDTXCIDARA THERAPEUTICS INC$29.4M0.39%1,092,796CommonSOLE
55287L101MBXMBX BIOSCIENCES INC$27.9M0.37%1,511,334CommonSOLE
65487U108NKTXNKARTA INC$26.9M0.36%10,805,129CommonSOLE
00509G209ABOSACUMEN PHARMACEUTICALS INC$25.7M0.34%14,932,063CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$25.4M0.34%4,563,211CommonSOLE
67080M103NRIXNURIX THERAPEUTICS INC$25.1M0.33%1,333,333CommonSOLE
81749D107SERASERA PROGNOSTICS INC-A$24.7M0.33%3,032,808CommonSOLE
008064107AEROVATE THERAPEUTICS INC$24.4M0.32%9,192,092CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$23.7M0.32%3,181,818CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$23.4M0.31%6,045,351CommonSOLE
15678C102CBLLCERIBELL INC$21.3M0.28%824,582CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$20.0M0.27%1,150,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$19.1M0.25%848,986CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$18.8M0.25%10,872,503CommonSOLE
014442107ALECALECTOR INC$18.3M0.24%9,695,228CommonSOLE
74365U107TARAPROTARA THERAPEUTIC INC$18.0M0.24%3,400,000CommonSOLE
12529R107CCCCC4 THERAPEUTICS INC$17.6M0.23%4,878,000CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$17.3M0.23%4,330,446CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$16.9M0.22%1,281,000CommonSOLE
10919W405DRUGBright Minds Biosciences Inc$16.6M0.22%460,829CommonSOLE
46565G1045E7ITEOS THERAPEUTICS INC$16.1M0.21%2,092,259CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC-ADR$15.3M0.20%1,093,477CommonSOLE
28617K101ELDNELEDON PHARMACEUTICALS INC$14.7M0.20%3,566,338CommonSOLE
457669307INSMINSMED INC$13.8M0.18%200,000CommonSOLE
98401F105XNCRXENCOR INC$13.2M0.18%575,000CommonSOLE
N44445109IMTXIMMATICS NV$12.4M0.17%1,750,000CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$11.6M0.15%4,666,667CommonSOLE
61023L207MNPRMONOPAR THERAPEUTICS INC$11.2M0.15%511,207CommonSOLE
88427A107THIRD HARMONIC BIO INC$9.9M0.13%960,620CommonSOLE
95075A107HOWLWEREWOLF THERAPEUTICS INC$9.1M0.12%6,144,881CommonSOLE
04335A105ARVNARVINAS INC$8.1M0.11%421,348CommonSOLE
G9TY5A101ZURAZURA BIO LTD$8.0M0.11%3,217,503CommonSOLE
G70077105PCSCPERCEPTIVE CAPITAL SOLUTIONS$7.6M0.10%750,000CommonSOLE
09077V100BIOABIOAGE LABS INC$7.6M0.10%1,310,589CommonSOLE
007002108TORCEURADICET BIO INC$7.3M0.10%7,541,000CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$7.2M0.10%967,000CommonSOLE
10170A100BOLDBOUNDLESS BIO INC$6.3M0.08%2,180,631CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$6.0M0.08%1,038,000CommonSOLE
N62509117NAMSWNEWAMSTERDAM PHARMA CO NV-27$4.7M0.06%333,333CommonSOLE
86889P208SRZNSURROZEN INC$4.1M0.05%282,580CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$3.6M0.05%546,554CommonSOLE
01671P100ALLKGUSDALLAKOS INC$1.4M0.02%1,129,931CommonSOLE
80706P103SRRKSCHOLAR ROCK HOLDING CORP$761,3640.01%17,616CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$532,2120.01%336,843CommonSOLE
80880W106SCLXUSDSCILEX HOLDING CO$441,8430.01%1,036,218CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.